Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

KORU Medical Systems (KRMD) EBITDA Margin (2020 - 2025)

KORU Medical Systems (KRMD) has disclosed EBITDA Margin for 10 consecutive years, with 8.34% as the latest value for Q3 2025.

  • On a quarterly basis, EBITDA Margin rose 970.0% to 8.34% in Q3 2025 year-over-year; TTM through Sep 2025 was 10.28%, a 2886.0% decrease, with the full-year FY2024 number at 19.16%, down 2636.0% from a year prior.
  • EBITDA Margin was 8.34% for Q3 2025 at KORU Medical Systems, down from 3.07% in the prior quarter.
  • In the past five years, EBITDA Margin ranged from a high of 140.9% in Q4 2023 to a low of 53.51% in Q2 2022.
  • A 5-year average of 10.37% and a median of 20.22% in 2021 define the central range for EBITDA Margin.
  • Peak YoY movement for EBITDA Margin: soared 17509bps in 2023, then crashed -15888bps in 2024.
  • KORU Medical Systems' EBITDA Margin stood at 96.34% in 2021, then tumbled by -135bps to 34.19% in 2022, then skyrocketed by 512bps to 140.9% in 2023, then plummeted by -113bps to 17.98% in 2024, then skyrocketed by 54bps to 8.34% in 2025.
  • Per Business Quant, the three most recent readings for KRMD's EBITDA Margin are 8.34% (Q3 2025), 3.07% (Q2 2025), and 12.92% (Q1 2025).